Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | Enhancing preventive therapy in patients with high-risk breast cancer

Inimfon Jackson • 13 Dec 2024
SABCS 2024
Breast Cancer Tamoxifen

Inimfon Jackson, MD, PhD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the development and evaluation of a risk communication and decision support tool designed to increase uptake of preventive therapy among women at high risk for invasive breast cancer. The study assessed the tool’s impact on knowledge, decision-making, and treatment preferences. While the tool reduced decisional uncertainty, it unexpectedly increased hesitancy towards therapy initiation. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Inimfon Jackson

Addressing access barriers and guideline-concordant breast cancer care
1:07
Addressing access barriers and guideline-concordant breast cancer care
Inimfon Jackson • 10 Dec 2025
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
2:28
Real-world use, disparities and outcomes of neoadjuvant chemo-IO in TNBC
Inimfon Jackson • 10 Dec 2025
Chemotherapy declination among patients with early-stage breast cancer and high Oncotype DX scores
1:53
Chemotherapy declination among patients with early-stage breast cancer and high Oncotype DX scores
Inimfon Jackson • 30 May 2025
Navigating discussions with patients who have high-risk genomics but are reluctant about chemo
0:57
Navigating discussions with patients who have high-risk genomics but are reluctant about chemo
Inimfon Jackson • 30 May 2025

Related Videos

CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals